{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T11:47:51Z","timestamp":1782388071967,"version":"3.54.5"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"The Talent Project of Tianchi Young Doctoral Program in Xinjiang Uygur Autonomous"},{"name":"Tianchi Innovation Leading Talent Program","award":["E43H4105"],"award-info":[{"award-number":["E43H4105"]}]},{"name":"The CAS Pioneer Hundred Talents Program"},{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82304875"],"award-info":[{"award-number":["82304875"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100013494","name":"West Light Foundation, Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["2023-XBQNXZ-009"],"award-info":[{"award-number":["2023-XBQNXZ-009"]}],"id":[{"id":"10.13039\/501100013494","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Xinjiang International Science & Technology Cooperation Key Program","award":["2025E01054"],"award-info":[{"award-number":["2025E01054"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Chem Res"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00044-026-03571-0","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T05:59:11Z","timestamp":1779775151000},"page":"1141-1160","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Design, synthesis, and activity study of heterocyclic derivatives as JAK inhibitors"],"prefix":"10.1007","volume":"35","author":[{"given":"Shukhrat","family":"Gaybullaev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MiaoMiao","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deng","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiale","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sardor","family":"Shakarov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuldash","family":"Takhirov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davron","family":"Turgunov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khurshed","family":"Bozorov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"3571_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","volume":"386","author":"K Ezzedine","year":"2015","unstructured":"Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386:74\u201384.","journal-title":"Lancet"},{"key":"3571_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.11","volume":"1","author":"M Picardo","year":"2015","unstructured":"Picardo M, Dell\u2019Anna ML, Ezzedine K, Hamzavi I, Harris JE, Parsad D, et al. Vitiligo. Nat Rev Dis Primers. 2015;1:15011.","journal-title":"Nat Rev Dis Primers"},{"key":"3571_CR3","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1111\/j.1365-4632.2011.05377.x","volume":"51","author":"C Kr\u00fcger","year":"2012","unstructured":"Kr\u00fcger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children\/adolescents and adults. Int J Dermatol. 2012;51:1206\u201312.","journal-title":"Int J Dermatol"},{"key":"3571_CR4","first-page":"CD003263","volume":"2","author":"ME Whitton","year":"2015","unstructured":"Whitton ME, Pinart M, Batchelor J, Leonardi J, Bee U, Gonz\u00e1lez Z, et al. Interventions for vitiligo. Cochrane Database Syst Rev. 2015;2:CD003263.","journal-title":"Cochrane Database Syst Rev"},{"key":"3571_CR5","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/j.1468-3083.2006.01897.x","volume":"21","author":"G Schmid-Ott","year":"2007","unstructured":"Schmid-Ott G, K\u00fcnsebeck H-W, Jecht E, Shimshoni R, Lazaroff I, Schallmayer S, et al. Stigmatization experience, coping and sense of coherence in vitiligo patients. J Eur Acad Dermatol Venereol. 2007;21:456\u201361.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3571_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13418","volume":"33","author":"RE Simons","year":"2020","unstructured":"Simons RE, Zevy DL, Jafferany M. Psychodermatology of vitiligo: psychological impact and consequences. Dermatol Ther. 2020;33:e13418.","journal-title":"Dermatol Ther"},{"key":"3571_CR7","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3390\/cimb47030191","volume":"47","author":"W Li","year":"2025","unstructured":"Li W, Dong P, Zhang G, Hu J, Yang S. Emerging therapeutic innovations for vitiligo treatment. Curr Issues Mol Biol. 2025;47:191.","journal-title":"Curr Issues Mol Biol"},{"key":"3571_CR8","doi-asserted-by":"publisher","first-page":"197","DOI":"10.5021\/ad.24.038","volume":"36","author":"SH Seong","year":"2024","unstructured":"Seong SH, Oh SH. Up-and-Coming drugs for the treatment of vitiligo. Ann Dermatol. 2024;36:197\u2013208.","journal-title":"Ann Dermatol"},{"key":"3571_CR9","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1159\/000537810","volume":"240","author":"HJ Ju","year":"2024","unstructured":"Ju HJ, Bae JM. Bridging molecular mechanism and clinical practice in vitiligo treatment: an updated review. Dermatology. 2024;240:474\u201386.","journal-title":"Dermatology"},{"key":"3571_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.22217","volume":"85","author":"WAA Fadaly","year":"2024","unstructured":"Fadaly WAA, Elshaier YAMM, Ali FEM, El-Bahrawy AH, Abdellatif KRA, Nemr MTM. Vicinal diaryl pyrazole with tetrazole\/urea scaffolds as selective angiotensin converting enzyme-1\/cyclooxygenase-2 inhibitors: design, synthesis, anti-hypertensive, anti-fibrotic, and anti-inflammatory. Drug Dev Res. 2024;85:e22217.","journal-title":"Drug Dev Res"},{"key":"3571_CR11","doi-asserted-by":"publisher","first-page":"107217","DOI":"10.1016\/j.phrs.2024.107217","volume":"204","author":"Y Lv","year":"2024","unstructured":"Lv Y, Mi P, Babon JJ, Fan G, Qi J, Cao L, et al. Small molecule drug discovery targeting the JAK-STAT pathway. Pharmacol Res. 2024;204:107217.","journal-title":"Pharmacol Res"},{"key":"3571_CR12","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1080\/17568919.2025.2545171","volume":"17","author":"AM Abd El-Hameed","year":"2025","unstructured":"Abd El-Hameed AM, Lotfallah AH, Nemr MTM, Abdelhady HK, Haredy HH, Sayed AM, et al. Novel di-aryl chalcone derived pyrazole linked to methane sulfonyl pharmacophore as potent selective COX-2 inhibitors; design, synthesis, molecular modeling, in vitro and in vivo anti-inflammatory activities. Future Medicinal Chem. 2025;17:1849\u201365.","journal-title":"Future Medicinal Chem"},{"key":"3571_CR13","doi-asserted-by":"publisher","first-page":"106210","DOI":"10.1016\/j.intimp.2020.106210","volume":"80","author":"P Xin","year":"2020","unstructured":"Xin P, Xu X, Deng C, Liu S, Wang Y, Zhou X, et al. The role of JAK\/STAT signaling pathway and its inhibitors in diseases. Int Immunopharmacol. 2020;80:106210.","journal-title":"Int Immunopharmacol"},{"key":"3571_CR14","doi-asserted-by":"publisher","first-page":"142578","DOI":"10.1016\/j.molstruc.2025.142578","volume":"1340","author":"WAA Fadaly","year":"2025","unstructured":"Fadaly WAA, Amin DME, Bakr RB, Nemr MTM, Ismail BS, Mohamed MFA. Design, synthesis and biological evaluation of phenoxyacetic acid derivatives linked to pyrazole scaffold as PPAR-\u03b1\/\u03b3 agonists and COX-2 inhibitors with dual antidiabetic\/anti-inflammatory activities. J Mol Structure. 2025;1340:142578.","journal-title":"J Mol Structure"},{"key":"3571_CR15","doi-asserted-by":"publisher","first-page":"112155","DOI":"10.1016\/j.ejmech.2020.112155","volume":"192","author":"P Xu","year":"2020","unstructured":"Xu P, Shen P, Yu B, Xu X, Ge R, Cheng X, et al. Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders. Eur J Medicinal Chem. 2020;192:112155.","journal-title":"Eur J Medicinal Chem"},{"key":"3571_CR16","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1038\/jid.2009.32","volume":"129","author":"JG van den Boorn","year":"2009","unstructured":"van den Boorn JG, Konijnenberg D, Dellemijn TAM, Wietze van der Veen JP, Bos JD, Melief CJM, et al. Autoimmune destruction of skin melanocytes by perilesional T Cells from vitiligo patients. J Investig Dermatol. 2009;129:2220\u201332.","journal-title":"J Investig Dermatol"},{"key":"3571_CR17","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jaad.2016.12.021","volume":"76","author":"JP Strassner","year":"2017","unstructured":"Strassner JP, Rashighi M, Ahmed Refat M, Richmond JM, Harris JE. Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity. J Am Acad Dermatol. 2017;76:847\u2013855.e5.","journal-title":"J Am Acad Dermatol"},{"key":"3571_CR18","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1146\/annurev-immunol-100919-023531","volume":"38","author":"ML Frisoli","year":"2020","unstructured":"Frisoli ML, Essien K, Harris JE. Vitiligo: mechanisms of pathogenesis and treatment. Annu Rev Immunol. 2020;38:621\u201348.","journal-title":"Annu Rev Immunol"},{"key":"3571_CR19","doi-asserted-by":"publisher","first-page":"e185785","DOI":"10.1172\/JCI185785","volume":"135","author":"K Ezzedine","year":"2025","unstructured":"Ezzedine K, Tannous R, Pearson TF, Harris JE. Recent clinical and mechanistic insights into vitiligo offer new treatment options for cell-specific autoimmunity. J Clin Investigation. 2025;135:e185785.","journal-title":"J Clin Investigation"},{"key":"3571_CR20","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1007\/s13555-025-01397-z","volume":"15","author":"AA Mohammed","year":"2025","unstructured":"Mohammed AA, Lengyel AS, Meznerics FA, Szondy I, Walter A, Szab\u00f3 B, et al. Efficacy and safety of JAK inhibitors in the management of vitiligo: a systematic review and meta-analysis. Dermatol Ther. 2025;15:1657\u201379.","journal-title":"Dermatol Ther"},{"key":"3571_CR21","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41586-021-04221-8","volume":"601","author":"Z Xu","year":"2022","unstructured":"Xu Z, Chen D, Hu Y, Jiang K, Huang H, Du Y, et al. Anatomically distinct fibroblast subsets determine skin autoimmune patterns. Nature. 2022;601:118\u201324.","journal-title":"Nature"},{"key":"3571_CR22","doi-asserted-by":"publisher","first-page":"4128","DOI":"10.4103\/jfmpc.jfmpc_112_24","volume":"13","author":"A Beard","year":"2024","unstructured":"Beard A, Trotter SC. JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician. J Family Med Prim Care. 2024;13:4128\u201334.","journal-title":"J Family Med Prim Care"},{"key":"3571_CR23","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1126\/science.abn8933","volume":"376","author":"CR Glassman","year":"2022","unstructured":"Glassman CR, Tsutsumi N, Saxton RA, Lupardus PJ, Jude KM, Garcia KC. Structure of a Janus kinase cytokine receptor complex reveals the basis for dimeric activation. Science. 2022;376:163\u20139.","journal-title":"Science"},{"key":"3571_CR24","doi-asserted-by":"publisher","first-page":"323","DOI":"10.4049\/jimmunol.1300344","volume":"191","author":"SJ Burke","year":"2013","unstructured":"Burke SJ, Goff MR, Lu D, Proud D, Karlstad MD, Collier JJ. Synergistic Expression of the CXCL10 Gene in Response to IL-1\u03b2 and IFN-\u03b3 Involves NF-\u03baB, Phosphorylation of STAT1 at Tyr701, and acetylation of Histones H3 and H4. J Immunology. 2013;191:323\u201336.","journal-title":"J Immunology"},{"key":"3571_CR25","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s10753-020-01322-w","volume":"44","author":"K Aota","year":"2021","unstructured":"Aota K, Yamanoi T, Kani K, Ono S, Momota Y, Azuma M. Inhibition of JAK-STAT signaling by baricitinib reduces interferon-\u03b3-induced CXCL10 production in human salivary gland ductal cells. Inflammation. 2021;44:206\u201316.","journal-title":"Inflammation"},{"key":"3571_CR26","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1080\/17512433.2023.2285011","volume":"16","author":"K Sardana","year":"2023","unstructured":"Sardana K, Muddebihal A, Khurana A. JAK inhibitors in vitiligo: what they hit and what they miss - an immunopathogenesis based exposition of existing evidence. Expert Rev Clin Pharmacol. 2023;16:1221\u20137.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"3571_CR27","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1146\/annurev-immunol-032712-095954","volume":"31","author":"SN Mueller","year":"2013","unstructured":"Mueller SN, Gebhardt T, Carbone FR, Heath WR. Memory T Cell subsets, migration patterns, and tissue residence. Annu Rev Immunol. 2013;31:137\u201361.","journal-title":"Annu Rev Immunol"},{"key":"3571_CR28","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jdermsci.2023.12.008","volume":"113","author":"S Inoue","year":"2024","unstructured":"Inoue S, Suzuki T, Sano S, Katayama I. JAK inhibitors for the treatment of vitiligo. J Dermatol Sci. 2024;113:86\u201392.","journal-title":"J Dermatol Sci"},{"key":"3571_CR29","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","volume":"6","author":"X Hu","year":"2021","unstructured":"Hu X, li J, Fu M, Zhao X, Wang W. The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6:402.","journal-title":"Signal Transduct Target Ther"},{"key":"3571_CR30","first-page":"343","volume":"3","author":"M Rashighi","year":"2015","unstructured":"Rashighi M, Harris JE. Interfering with the IFN-\u03b3\/CXCL10 pathway to develop new targeted treatments for vitiligo. Ann Transl Med. 2015;3:343.","journal-title":"Ann Transl Med"},{"key":"3571_CR31","doi-asserted-by":"publisher","first-page":"8064","DOI":"10.3390\/molecules28248064","volume":"28","author":"I Rygu\u0142a","year":"2023","unstructured":"Rygu\u0142a I, Pikiewicz W, Kamini\u00f3w K. Novel janus kinase inhibitors in the treatment of dermatologic conditions. Molecules. 2023;28:8064.","journal-title":"Molecules"},{"key":"3571_CR32","first-page":"8064","volume":"90","author":"MY Huang","year":"2015","unstructured":"Huang MY, Armstrong AW. Janus-kinase inhibitors in dermatology: a review of their use in psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease. Indian J Dermatol Venereol Leprol. 2015;90:8064.","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"3571_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/slct.202504601","volume":"10","author":"MTM Nemr","year":"2025","unstructured":"Nemr MTM, Fadaly WAA, Abdelaziz MA. Pharmaceutical applications of Di\/Tri-Aryl pyrazole derivatives: a review on recent updates. ChemistrySelect. 2025;10:e04601.","journal-title":"ChemistrySelect"},{"key":"3571_CR34","doi-asserted-by":"publisher","first-page":"e29221","DOI":"10.1016\/j.heliyon.2024.e29221","volume":"10","author":"FM Abdelrazek","year":"2024","unstructured":"Abdelrazek FM, Zaki MEA, Al-Hussain SA, Farag B, Hebishy AM, Abdelfattah MS, et al. Facile one-pot synthesis and in silico study of new heterocyclic scaffolds with 4-pyridyl moiety: mechanistic insights and X-ray crystallographic elucidation. Heliyon. 2024;10:e29221.","journal-title":"Heliyon"},{"key":"3571_CR35","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1016\/j.cclet.2021.12.099","volume":"33","author":"D Liu","year":"2022","unstructured":"Liu D, Ge H, Xu F, Xu Y, Liu W, Li H, et al. Design, synthesis and SAR study of 2-aminopyridine derivatives as potent and selective JAK2 inhibitors. Chin Chem Lett. 2022;33:2969\u201374.","journal-title":"Chin Chem Lett"},{"key":"3571_CR36","doi-asserted-by":"publisher","first-page":"132200","DOI":"10.1016\/j.molstruc.2021.132200","volume":"1253","author":"H Zhou","year":"2022","unstructured":"Zhou H, Jiang J, Lu J, Ran D, Gan Z. Synthesis and biological evaluation of novel 2,4-dianilinopyrimidine derivatives as potent dual janus kinase 2 and histone deacetylases inhibitors. J Mol Structure. 2022;1253:132200.","journal-title":"J Mol Structure"},{"key":"3571_CR37","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.bmc.2010.11.057","volume":"19","author":"SH Yang","year":"2011","unstructured":"Yang SH, Khadka DB, Cho SH, Ju H-K, Lee KY, Han HJ, et al. Virtual screening and synthesis of quinazolines as novel JAK2 inhibitors. Bioorganic Medicinal Chem. 2011;19:968\u201377.","journal-title":"Bioorganic Medicinal Chem"},{"key":"3571_CR38","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1007\/s11164-018-03731-x","volume":"45","author":"A Nasrullaev","year":"2019","unstructured":"Nasrullaev A, Bozorov K, Bobakulov K, Zhao J, Nie LF, Turgunov KK, et al. Synthesis, characterization, and antimicrobial activity of novel hydrazone-bearing tricyclic quinazolines. Res Chem Intermed. 2019;45:2287\u20132300.","journal-title":"Res Chem Intermed"},{"key":"3571_CR39","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3390\/molecules28030978","volume":"28","author":"AM Alsibaee","year":"2023","unstructured":"Alsibaee AM, Al-Yousef HM, Al-Salem HS. Quinazolinones, the winning horse in drug discovery. Molecules. 2023;28:978.","journal-title":"Molecules"},{"key":"3571_CR40","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.3390\/molecules30132791","volume":"30","author":"D Turgunov","year":"2025","unstructured":"Turgunov D, Nie L, Nasrullaev A, Murtazaeva Z, Wang B, Kholmurodova D, et al. Synthesis of Novel 7-Phenyl-2,3-Dihydropyrrolo[2,1-b]Quinazolin-9(1H)-ones as cholinesterase inhibitors targeting alzheimer\u2019s disease through suzuki\u2013miyaura cross-coupling reaction. Molecules. 2025;30:2791.","journal-title":"Molecules"},{"key":"3571_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34340-3","volume":"13","author":"X-W Chen","year":"2022","unstructured":"Chen X-W, Rao L, Chen J-L, Zou Y. Unexpected assembly machinery for 4(3H)-quinazolinone scaffold synthesis. Nat Commun. 2022;13:6522.","journal-title":"Nat Commun"},{"key":"3571_CR42","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ejmech.2019.03.004","volume":"170","author":"D Das","year":"2019","unstructured":"Das D, Hong J. Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry. Eur J Medicinal Chem. 2019;170:55\u201372.","journal-title":"Eur J Medicinal Chem"},{"key":"3571_CR43","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.biochi.2026.02.015","volume":"245","author":"G Antoniolli","year":"2026","unstructured":"Antoniolli G, Nemr MTM, Marques SPD, Sebakhy KO, Barbosa EG, Trevisan MTS, et al. Discovery of 6,7-dimethoxyquinazoline-hydrazide hybrids as dual inhibitors of acetylcholinesterase and \u03b2-secretase. Biochimie. 2026;245:88\u201398.","journal-title":"Biochimie"},{"key":"3571_CR44","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1021\/acs.jmedchem.1c01765","volume":"65","author":"CR Wellaway","year":"2022","unstructured":"Wellaway CR, Baldwin IR, Bamborough P, Barker D, Bartholomew MA, Chung C-w, et al. Investigation of janus kinase (JAK) inhibitors for lung delivery and the importance of aldehyde oxidase metabolism. J Medicinal Chem. 2022;65:633\u201364.","journal-title":"J Medicinal Chem"},{"key":"3571_CR45","doi-asserted-by":"publisher","first-page":"106765","DOI":"10.1016\/j.bioorg.2023.106765","volume":"140","author":"J Xiang","year":"2023","unstructured":"Xiang J, Wang Y, Wang W, Yu J, Zheng L, Hong Y, et al. Design, synthesis, and pharmacological evaluation of quinazoline derivatives as novel and potent pan-JAK inhibitors. Bioorganic Chem. 2023;140:106765.","journal-title":"Bioorganic Chem"},{"key":"3571_CR46","doi-asserted-by":"crossref","unstructured":"Xie B, Shi M, Tang D, Yang S, Zeng Y, Nie L, et al. Design and synthesis of novel indolinone Aurora B kinase inhibitors based on fragment-based drug discovery (FBDD). Mol Diversity. 2025.","DOI":"10.21203\/rs.3.rs-7130864\/v1"},{"key":"3571_CR47","doi-asserted-by":"publisher","first-page":"4467","DOI":"10.1007\/s11030-023-10794-5","volume":"28","author":"L Maji","year":"2024","unstructured":"Maji L, Sengupta S, Purawarga Matada GS, Teli G, Biswas G, Das PK, et al. Medicinal chemistry perspective of JAK inhibitors: synthesis, biological profile, selectivity, and structure activity relationship. Mol Diversity. 2024;28:4467\u2013513.","journal-title":"Mol Diversity"},{"key":"3571_CR48","doi-asserted-by":"publisher","first-page":"107506","DOI":"10.1016\/j.bioorg.2024.107506","volume":"149","author":"M Shan","year":"2024","unstructured":"Shan M, Zhao X, Sun P, Qu X, Cheng G, Qin L-P. Revisiting Structure-activity Relationships: Unleashing the potential of selective Janus kinase 1 inhibitors. Bioorganic Chem. 2024;149:107506.","journal-title":"Bioorganic Chem"},{"key":"3571_CR49","doi-asserted-by":"publisher","first-page":"8929","DOI":"10.1021\/acs.jmedchem.3c00519","volume":"66","author":"HM Gordhan","year":"2023","unstructured":"Gordhan HM, Miller ST, Clancy DC, Ina M, McDougal AV, Cutno DQK, et al. Eyes on topical ocular disposition: the considered design of a lead janus kinase (JAK) inhibitor that utilizes a unique azetidin-3-amino bridging scaffold to attenuate off-target kinase activity, while driving potency and aqueous solubility. J Medicinal Chem. 2023;66:8929\u201350.","journal-title":"J Medicinal Chem"},{"key":"3571_CR50","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1021\/acsmedchemlett.2c00051","volume":"13","author":"SP Henry","year":"2022","unstructured":"Henry SP, Liosi M-E, Ippolito JA, Cutrona KJ, Krimmer SG, Newton AS, et al. Conversion of a false virtual screen hit into selective JAK2 JH2 domain binders using convergent design strategies. ACS Medicinal Chem Lett. 2022;13:819\u201326.","journal-title":"ACS Medicinal Chem Lett"},{"key":"3571_CR51","doi-asserted-by":"publisher","DOI":"10.1111\/sji.13000","volume":"93","author":"A Aghamajidi","year":"2021","unstructured":"Aghamajidi A, Raoufi E, Parsamanesh G, Jalili A, Salehi-Shadkami M, Mehrali M, et al. The attentive focus on T cell-mediated autoimmune pathogenesis of psoriasis, lichen planus and vitiligo. Scand J Immunol. 2021;93:e13000.","journal-title":"Scand J Immunol"},{"key":"3571_CR52","first-page":"501","volume":"36","author":"Q Li","year":"2020","unstructured":"Li Q, Qi Q, Yang X-Q, Yang F-M, Lin Z-M, Chen F-X, et al. DZ2002 improves psoriasis-like lesions of guinea pig via inhibiting secretion of chemokines in keratinocytes. Chin Pharmacol Bull. 2020;36:501\u20137.","journal-title":"Chin Pharmacol Bull"}],"container-title":["Medicinal Chemistry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00044-026-03571-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00044-026-03571-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00044-026-03571-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T11:04:45Z","timestamp":1782385485000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00044-026-03571-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["3571"],"URL":"https:\/\/doi.org\/10.1007\/s00044-026-03571-0","relation":{},"ISSN":["1054-2523","1554-8120"],"issn-type":[{"value":"1054-2523","type":"print"},{"value":"1554-8120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"20 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}